Aurobindo Pharma to Acquire 20% Additional Stake in Chinese Joint Venture Luoxin Aurovitas

Aurobindo Pharma Ltd has announced that its wholly owned subsidiary, Helix Healthcare B.V., has entered into a binding agreement with Shandong Luoxin Pharmaceutical Group Stock Co., Ltd., China to acquire 20% additional ownership in Luoxin Aurovitas Pharma (Chengdu) Co. Ltd, China, a 30:70 joint venture company between Helix and Shandong Luoxin. The acquisition is expected to be completed within the next three months, with the right to acquire balance 50% stake by December 2029. Luoxin Aurovitas, incorporated on March 25, 2019, has a net worth of USD 15.29 mn as on September 30, 2025 and has reported a turnover of USD 2.34 mn during FY 2024-25. The acquisition is aimed at expanding the manufacturing capabilities and meeting market demand.